These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 20943082)

  • 21. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
    Ouyang DW; Shapiro DE; Lu M; Brogly SB; French AL; Leighty RM; Thompson B; Tuomala RE; Hershow RC
    AIDS; 2009 Nov; 23(18):2425-30. PubMed ID: 19617813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
    J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
    Macías J; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Pineda JA;
    HIV Clin Trials; 2012; 13(2):61-9. PubMed ID: 22510353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
    Podzamczer D; Tiraboschi JM; Mallolas J; Curto J; Cárdenes MA; Casas E; Castro A; Echevarría S; Leal M; Lopez Bernaldo de Quirós JC; Moreno S; Puig T; Ribera E; Villalonga C; Gómez-Sirvent JL; García-Henarejos JA; Lopez-Aldeguer J; Barrufet P; Force L; Santos I; Sanz J
    Curr HIV Res; 2012 Sep; 10(6):513-20. PubMed ID: 22716109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
    Podzamczer D; Olmo M; Sanz J; Boix V; Negredo E; Knobel H; Domingo P; Pineda JA; Vilades C; Quero JH; Force L; Lahoz JG; Muñoz P; Llibre JM; Mariño A; Ortega E; Dalmau D; Gatell JM; Antón E; Sola J; Galindo MJ; Pedrol E; Sanz J; Lima JT; Flores J;
    J Acquir Immune Defic Syndr; 2009 Apr; 50(4):390-6. PubMed ID: 19214120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial.
    Wester CW; Stitelman OM; deGruttola V; Bussmann H; Marlink RG; van der Laan MJ
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):981-8. PubMed ID: 22309114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
    Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Van Welzen B; Mudrikova T; Arends J; Hoepelman A
    HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
    HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
    J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis.
    Sun J; Liu L; Shen J; Qi T; Wang Z; Song W; Zhang R; Lu H
    PLoS One; 2015; 10(7):e0133242. PubMed ID: 26207639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
    Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
    Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Notter J; Bregenzer A; Vernazza P; Kahlert CR
    Swiss Med Wkly; 2019 Apr; 149():w20053. PubMed ID: 31017649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
    Coffie PA; Tonwe-Gold B; Tanon AK; Amani-Bosse C; Bédikou G; Abrams EJ; Dabis F; Ekouevi DK
    BMC Infect Dis; 2010 Jun; 10():188. PubMed ID: 20576111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.